Champions Oncology, Inc.

NASDAQ:CSBR

Biotechnology

Healthcare
$4.44 -1.17%

-$0.08 today

Market cap
$61.80M
Beta
0.40
P/E (TTM)
-41.0
EPS (TTM)
-$0.16
52W Low $5.50High $9.63

Volume 0.01M

Average 0.01M

CSBR Common Stock Repurchased

Cash spent buying back the company's own shares.

Champions Oncology, Inc.NASDAQ: CSBR

Common Stock Repurchased · Q3 FY2026 · quarter ended Jan 2026

Common stock repurchased outflow grows to $0

Q3 FY2026 common stock repurchased was $0, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was $0.

Context

  • Common stock repurchased amounted to 0.0% of revenue in FY2025, down 1.3 pp from a year earlier.
  • Common stock repurchased increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJan 2026
$0— QoQ
Last fiscal yearApr 2025
$0+100.0% YoY
LTMJan 2026
$0— YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
+100.0%

Common Stock Repurchased vs competitors

How CSBR compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock repurchased is compared through growth and share of revenue rather than absolute size.
  • Common stock repurchased amounts to 0.0% of revenue for CSBR, versus a peer median of 0.0%.
CSBR Competitors
Common Stock Repurchased for CSBR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$4.77M USD+92.2%——
STROSutro Biopharma, Inc.LTM Mar 2026$60K USD+150.0%—0.1%
CSBRChampions Oncology, Inc.LTM Jan 2026$0 USD——0.0%
STTKShattuck Labs, Inc.LTM Mar 2026$0 USD+100.0%—0.0%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$0 USD-100.0%——
IFRXInflaRx N.V.LTM Mar 2026€0 EUR——0.0%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$0 USD——0.0%
CNTBConnect Biopharma Holdings LimitedFY2025$0 USD——0.0%
IMAImageneBio IncLTM Mar 2026$0 USD———
KLRSKalaris Therapeutics IncLTM Mar 2026$0 USD———
Peer median (excluding CSBR) —+96.1%—0.0%

Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Net Income334K548K(5.34M)(7.28M)4.7M
Depreciation & Amortization1.18M1.63M2.25M1.87M1.64M
Deferred Income Tax49K01M00
Stock-Based Compensation598K912K864K1.12M654K
Change in Working Capital(4.17M)2.34M4.23M(3.82M)(621K)
Accounts Receivables(2.27M)(2.82M)1.31M(1.99M)(1.44M)
Inventory(1.1M)0000
Accounts Payables(1.25M)974K2.47M465K(1.75M)
Other Working Capital441K4.18M470K(2.3M)2.56M
Other Non-Cash Items323K1.07M952K1.98M1.01M
Operating Cash Flow(1.68M)6.5M3.96M(6.14M)7.39M
Capital Expenditures(3.28M)(2.38M)(2.87M)(836K)(389K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities112K0000
Investing Cash Flow(3.17M)(2.38M)(2.87M)(836K)(389K)
Debt Repayment(174K)00(146K)(150K)
Common Stock Issued1.37M207K85K253K320K
Common Stock Repurchased00(74K)(634K)0
Dividends Paid00000
Other Financing Activities0085K253K0
Financing Cash Flow1.2M207K11K(527K)170K
Effect of Forex Changes0017K00
Net Change in Cash(3.66M)4.32M1.11M(7.5M)7.17M
Free Cash Flow(4.96M)4.11M1.08M(6.97M)7M

Champions Oncology, Inc.

NASDAQ:CSBR

Intrinsic Alpha fair value

Locked

Current Price

$4.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.